Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AAAscentage Pharma Group International logo

Ascentage Pharma Group International (AAPG)

NASDAQ Global Market · Currency in USD
$15.44 ▲ +0.52 (+3.49%)
At close: Oct 23, 4:00 PM ET. Market closed.
$15.56 ▲ +0.12 (+0.78%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$14.92
Open
$15.46
Day's Range
$15.25 – $15.46
52 Week Range
$14.46 – $35.07
Volume
9,295
Avg. Volume
9,429
Market Cap
$1.44B
Beta (5Y Monthly)
0.66
PE Ratio (TTM)
--
EPS (TTM)
-$15.50
Earnings Date
Mar 31, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$46.00

Profile: Ascentage Pharma Group International

Sector
Healthcare
Industry
Biotechnology
Full-time employees
767
CEO
Dajun Yang

Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation.

Earnings

Next report: Wed, Mar 31, 2027
EPS estimate -$0.30 · Revenue est. $49.77M
DateEst.Actual
Aug 18, 2026-$0.22-$1.30Miss
Mar 24, 2026-$0.83-$0.65Beat
Aug 20, 2025–-$0.96
Mar 27, 2025$0.02-$1.00Miss
Aug 22, 2024–$0.31
Dec 31, 2023–-$1.02

Analyst view

Consensus price target
$46.00 ▲ +197.9%
Range $40.00 – $51.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on AAPG and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.